μΈνν
μΈννμ κ·Έλ μμ± λ° κ·Έλ μμ± λ³μκ· λͺ¨λμ λν΄ κ΄λ²μν νμ±μ κ°λ **4μΈλ μΈνλ‘μ€ν¬λ¦°** νμμ μ λλ€. * **ꡬ쑰μ μ₯μ :** **μμͺ½μ± μ΄μ¨ ꡬ쑰**(μ μ νκ° μ€μ±)λ₯Ό κ°μ§κ³ μμ΄ κ·Έλ μμ±κ· μ μΈλ§ ν¬λ¦°μ λΉ λ₯΄κ² ν΅κ³Όν μ μμ΅λλ€. * **λ² νλ½νλ§μ μμ μ±:** AmpC λ² νλ½νλ§μ λ₯Ό ν¬ν¨ν λ§μ λ² νλ½νλ§μ μ μν κ°μλΆν΄μ λμ λ΄μ±μ κ°μ§λ©°, μ΄λ€μ μμ±μ μ½κ² μ λνμ§ μμ΅λλ€. * **νκ· μ€ννΈλΌ:** λ Ήλκ· (*Pseudomonas aeruginosa*) λ° μ₯λ΄μΈκ· κ³Ό(*Enterobacteriaceae*)μ λν΄ μ°μν ν¨κ³Ό(μΈννμ§λ€κ³Ό κ°μ 3μΈλ μ½λ¬Όκ³Ό μ μ¬)λ₯Ό μ 곡νλ©΄μλ ν¬λμκ΅¬κ· λ° μ°μμκ΅¬κ· κ³Ό κ°μ κ·Έλ μμ± νΈκΈ°μ± κ· μ λν κ°λ ₯ν νμ±μ μ μ§ν©λλ€. > **μμ μμ :** λμ λΉμ©, κ²½κ΅¬μ© μ μ μ λΆμ¬, λΉλ²ν ν¬μ¬ μꡬ(μ§§μ λ°κ°κΈ°)λ‘ μΈν΄ μΈννμ μΌλ°μ μΌλ‘ λ€μ λ΄μ± κ°μΌμ΄ μμ¬λκ³ λ€λ₯Έ λ² νλ½νκ³, μλ―Έλ ΈκΈλ¦¬μ½μ¬μ΄λκ³ λλ ν루μ€λ‘ν΄λλ‘ κ³ μ½λ¬Όμ΄ ν¨κ³Όκ° μκ±°λ κΈκΈ°μΈ μ€μ¦ μ μ νμ(μ: μ μ λ§μμ§ λλ ν¨νμ¦ λ°λ €κ²¬)μκ² μ νμ μΌλ‘ μ¬μ©λ©λλ€.
μμ© κΈ°μ : Cefepime is a **bactericidal**, time-dependent antibiotic that works by disrupting bacterial cell wall synthesis. * **Target Binding:** It rapidly penetrates the bacterial cell envelope and binds with high affinity to specific **penicillin-binding proteins (PBPs)**, primarily PBP 3 and PBP 2. * **Inhibition:** Binding to PBPs inhibits the transpeptidation enzyme responsible for cross-linking peptidoglycan strands. * **Cell Lysis:** The lack of a structurally sound cell wall β activation of bacterial autolysins β **osmotic cell lysis** and bacterial death.
λλ¬Ό μ’ λ³ μ©λ
- For susceptible infections in foals (gram-negative infections) Β· 11 mg/kg IV q8h Β· IV Β· q8h
- Neonates with poor aminoglycoside kinetics or documented multi-resistant infections Β· 11 mg/kg IV q8h Β· IV Β· q8h Β· Use has been limited primarily to neonates
- For susceptible infections Β· 40 mg/kg IV q6h Β· IV Β· q6h
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to cefepime or other cephalosporins
- Caution in patients with severe renal impairment (dosage adjustment required)
μ΄μλ°μ
- Loose stools or diarrhea
- Pain on IM injection
- Injection site inflammation
- Hypersensitivity reactions (rash, anaphylaxis)
- Neurologic effects (encephalopathy, seizures) in patients with renal dysfunction
μ½λ¬Ό μνΈμμ©
- Aminoglycosides Β· Potential for increased risk of nephrotoxicity; monitor renal function closely.
λͺ¨λν°λ§
- Clinical efficacy (resolution of infection signs)
- Renal function (especially in patients with pre-existing renal insufficiency or when used concurrently with nephrotoxic drugs)
κ³Όμ©λ
No specific information is available for acute toxicity in veterinary patients. In humans with impaired renal function, inadvertent overdoses have led to **encephalopathy, seizures, and neuromuscular excitability**. Treatment should be supportive, and renal function must be monitored.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.